



---

For additional information contact:  
Jody Donohue, APR  
Communications Manager  
Office: 913.945.4405  
Mobile: 913.333.6329  
Email: [jody.donohue@ceva.com](mailto:jody.donohue@ceva.com)

---

For Immediate Release

## Ceva receives US patent for innovative delivery system of treating poultry hatchlings through gel application

(Lenexa, Kansas, January 6, 2014) – Poultry producers now have access to a new method for administering vaccines, probiotics and nutritional supplements in the hatchery through a soft edible gel.

The new system recently patented by Ceva Animal Health, (US Patent No. 8,794,185) covers a soft gel in small beadlets which stick to the down of the chicks. When the chicks preen these beadlets, the vaccine, or treatment, is uniformly ingested

“Using a gel in this form provides a distinct advantage over traditional liquid carrier applications,” said Gary Baxter, Vice President of Sales and Marketing - US Poultry. “The gel allows for consistent suspension of the treatment without the need for constant stirring of a liquid medium. Gel droplets are also advantageous because they do not reduce the body temperature of chicks, as is often the case with conventional water-based applications.”



This unique way of administering treatments to poultry hatchlings has been demonstrated to be particularly successful for the administration of coccidiosis and salmonella vaccines. Ceva has also successfully completed trials using its patented gel-droplet delivery method to apply probiotics available on the US market, either alone or in combination with their coccidiosis vaccine.

“Ceva has moved on from being vaccine-centered to a company which looks at the science of vaccinology through the practical needs of our customers. We want to deliver, in addition to innovative vaccines, innovative solutions that bring value to or simplify the everyday lives of poultry producers,” said Dr. Sylvain Comte, the head of Ceva’s Poultry Franchise.

###

**About Ceva Santé Animale:** Ceva Santé Animale was created in 1999 and is a global veterinary group specialized in research, development, production and marketing of pharmaceutical products and vaccines for companion animals, ruminants, swine and poultry. The Group is present in 110 countries and turns in double-digit annual growth every year, reaching turnover in excess of €700 million in 2013. Today, Ceva Santé Animale employs over 3,500 people around the world. Since 2007, the management and employees have been the majority shareholders of Ceva Santé Animale, chaired by Dr. Marc Prikazsky.

**About Ceva Animal Health:** Since Ceva acquired the Biomune Company in 2005, production capabilities have steadily grown. Ceva currently supplies more than 50 countries with critical poultry vaccines. This growth means we are continually investing in production, research and development to offer novel vector and custom vaccines to our customers. The company’s North American headquarters is in Lenexa, Kansas. Visit [www.ceva.us](http://www.ceva.us).